POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL

POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL

Bibliographic Details
Main Authors:	H. Lambers Heerspink, R.D. Toto, N. Jongs, P. Vart, G.M. Chertow, F.F. Hou, J.J.V. McMurray, R. Pecoits-Filho, R. Correa-Rotter, P. Rossing, C.D. Sjöström, B.V. Stefánsson, K. Umanath, A.M. Langkilde, D.C. Wheeler
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024921010160

Similar Items

POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL
by: G.M. Chertow, et al.
Published: (2021-04-01)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
by: Glenn M. Chertow, et al.
Published: (2023-05-01)

Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial
by: Kentaro Oka, et al.
Published: (2023-12-01)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
by: Akihiko Koshino, et al.
Published: (2023-11-01)

The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
by: Gabriella di Mauro, et al.
Published: (2022-02-01)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020-02-01)

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials
by: Ankeet S. Bhatt, et al.
Published: (2024-03-01)

POS-336 THE IMPACT OF CHRONIC KIDNEY DISEASE AND CLINICAL EVENTS ON PATIENT HEALTH RELATED QUALITY OF LIFE IN DAPA-CKD
by: P. MCEWAN, et al.
Published: (2021-04-01)

The DAPA‐DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity—A longitudinal cohort study
by: Petra Hanson, et al.
Published: (2022-11-01)

Evidence-based Appraisal of the DAPA-HF Trial
by: Anthony Sengul, et al.
Published: (2020-10-01)

Results of the DAPA-CKD trial and their impact on clinical practice
by: O.V. Bilchenko
Published: (2023-06-01)

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
by: Pankaj Jariwala, MD, DNB, DNB, MNAMS, FACC, FSCAI, et al.
Published: (2021-09-01)

The DAPA Trial in the Context of Previous Prophylactic ICD Landmark Trials
by: Danielle Haanschoten, et al.
Published: (2021-10-01)

CCNP TSHOOT 642-832 : quick reference /
by: Stewart, Brent, author
Published: (2010)

DAPA-HF study: Are the benefits uniform across non-diabetic subgroups
by: Anil Pareek, et al.
Published: (2020-09-01)

Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT
by: Lamb, S, et al.
Published: (2018)

CCNP TSHOOT 642-832 [electronic resource] : cert kit /
by: Stewart, Brent, author
Published: (2010)

Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data
by: Zh. D. Kobalava, et al.
Published: (2020-06-01)

Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial
by: Lamb, S, et al.
Published: (2018)

DAPA: Differential Analysis aided Power Attack on (Non-) Linear Feedback Shift Registers
by: Siang Meng Sim, et al.
Published: (2020-12-01)

DAPA: Differential Analysis aided Power Attack on (Non-) Linear Feedback Shift Registers
by: Siang Meng Sim, et al.
Published: (2020-12-01)

832 Overcome solid tumor immunosuppression for T cells-mediated cancer elimination
by: Yuan Liu, et al.
Published: (2023-11-01)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
by: Kim HC, et al.
Published: (2023-04-01)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
by: Priya Vart, et al.
Published: (2022-09-01)

The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
by: Cohen-Jonathan, E, et al.
Published: (2001)

Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria
by: Anna Camps-Vilaró, et al.
Published: (2020-07-01)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
by: Viktor Rotbain Curovic, et al.
Published: (2022-04-01)

P832: Discovering phenotype-gene correlations using Variant WorkBench
by: Yiran Guo, et al.
Published: (2024-01-01)

Ó Deus, não permaneças em silêncio! (Sl 83,2a)
by: Fabio da Silveira Siqueira, et al.
Published: (2023-12-01)

Michael Fjeldsøe: Kulturradikalismens musik, København: Museum Tusculanums Forlag 2013, 832 S.
by: Frithjof Strauß
Published: (2017-03-01)

Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trial
by: Atherton, N, et al.
Published: (2016)

Is Dapagliflozin future for CKD?
by: Yumna Zafar, et al.
Published: (2022-02-01)

Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT
by: Sarah E Lamb, et al.
Published: (2018-05-01)

Olive Oil Lipophenols Induce Insulin Secretion in 832/13 β-Cell Models
by: Maria Cristina Caroleo, et al.
Published: (2021-07-01)

Plutarh: Moralia 827d–832a - Zakaj se ne smemo zadolževati?
by: Jerneja Kavčič
Published: (2015-12-01)

Cardiovascular risk in systemic autoimmune diseases – authors' reply
by: Conrad, N, et al.
Published: (2023)

P832: CLINICAL OUTCOMES AND IMMUNE RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH SEVERE APLASTIC ANEMIA
by: R. Rajput, et al.
Published: (2022-06-01)

Dapagliflozin in patients with type 2 diabetes mellitus
by: Theodosios D. Filippatos, et al.
Published: (2015-02-01)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
by: M. Arow, et al.
Published: (2020-01-01)

Not so critical appraisal of dapagliflozin
by: Doggrell SA
Published: (2014-08-01)